Q4 2024 Earnings Call Transcript March 11, 2025 Operator: Welcome to the SIGA Business Update Call. Before we turn the call ...

Q3 2025 Earnings Call Transcript March 11, 2025 Champions Oncology, Inc. beats earnings expectations. Reported EPS is $0.3181 ...

Concentra Biosciences offers $3/share + CVR for Acelyrin, outperforming Alumis' bid. Read why I rate SLRN stock a Sell at ...

Daniel Luckshire; Chief Financial Officer, Executive Vice President, Corporate Secretary; SIGA Technologies Inc Welcome to the CIA business update call. Before returning the call over to CIA ...

FY 2024 net revenue of $23.6 million, driven by net revenue of $12.0 million during fourth quarter of 2024Entered into asset purchase agreement ...

The Nibbles credit card offers rewarding pet-related benefits, the most valuable of which is its pet insurance that covers up ...

For roughly about 65 million years, the forests of the Amazonian were resilient to changes in the climate. But that is ...

The bill's proponents suggest it would increase intellectual diversity. Its opponents consider it an attack on research and ...

We share reporting tips from an expert attorney, an immigration researcher, and a prizewinning journalist who cover ...

The deal caps a turbulent three years for 2seventy bio. The company served as the oncology business of Bluebird Bio until Bluebird spun out 2seventy in 2021.

Zevra Therapeutics, Inc. ( NASDAQ: ZVRA) Q4 2024 Earnings Conference Call March 11, 2025 4:30 PM ET Nichol Ochsner - VP, IR and Corporate Communications Neil McFarlane - President and CEO LaDuane ...